NexPoint Life Sciences III DST — Form D/A
NexPoint Life Sciences III DST of DALLAS, TX, a pooled investment fund, filed a Form D amendment with the SEC on 2026-01-13. The offering totals $30.7M, of which $25.2M was reported sold. Industry: Other Real Estate.
Offering
- Filed: 2026-01-13
- Form: D/A
- Accession: 0002008210-26-000001
- Industry: Other Real Estate
- Exemptions: 06c,3C,3C.1,3C.5
- Total offering: $30.7M
- Amount sold: $25.2M
- Remaining: $5.5M
- Minimum investment: $100K
- Investors: 81
- Date of first sale: 2024-01-25
- Security types: equity, fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-503969
Issuer
- Name: NexPoint Life Sciences III DST
- CIK: 0002008210
- Entity type: Other
- Jurisdiction: DELAWARE
- Incorporated: 2023
- Address: 300 CRESCENT COURT, DALLAS, TX, 75201
- Phone: (833) 697-6246
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Matt McGraner | Executive Officer | Dallas, TX |
| N/A NexPoint Real Estate Advisors IV, L.P. | Executive Officer | Dallas, TX |
| Brian Mitts | Executive Officer | Dallas, TX |
| N/A NREA LS III Contributor, LLC | Executive Officer | Dallas, TX |
| N/A NREA LS III Manager, LLC | Executive Officer | Dallas, TX |
Other filings by this issuer (15)
More